Update on chronic hepatitis C.
Strategies for the diagnosis and treatment of chronic hepatitis C continue to evolve. Liver biopsy is now used selectively rather than routinely, and the combination peginterferon plus ribavirin is the treatment of choice for the majority of patients.
Ahmed
Aijaz
A
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, Calif., USA.
Keeffe
Emmet B
EB
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D001706:Biopsy; D000075202:Contraindications; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007159:Immunologic Tests; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects; D009626:Terminology as Topic; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a